Healthcare Triangle, Inc. reported a significant revenue increase to $28.2 million for the nine months ended September 30, 2026, compared to $10.8 million in the prior year, driven by business expansion. However, the company continues to operate at a loss, with a net loss from operations of $9.7 million for the period and a total asset base that grew to $72.7 million following substantial increases in intangible assets.
Healthcare Triangle, Inc. effected a 1-for-20 reverse stock split of its common stock effective October 26, 2026. The action reduced the number of outstanding shares from approximately 17.7 million to 886,587 to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
Healthcare Triangle stockholders approved a proposal to authorize the Board of Directors to effect one or more reverse stock splits at a ratio ranging from 1-for-2 to 1-for-25. Additionally, shareholders approved an amendment to the 2020 Stock Incentive Plan and authorized potential share issuances exceeding 20% of outstanding stock at below-market prices for Nasdaq compliance purposes.
Healthcare Triangle received a Staff Delisting Determination from Nasdaq on October 1, 2026, for failing to maintain the $1.00 minimum bid price requirement. Because the company has already effected cumulative reverse stock splits exceeding a 1-for-250 ratio over the last two years, it is ineligible for a standard 180-day compliance period. The company intends to appeal the delisting determination to a Nasdaq Hearings Panel, which will stay the suspension of its common stock pending a decision.
Healthcare Triangle, Inc. entered into an amendment to its existing Equity Purchase Agreement with Hudson Global Ventures, LLC. The amendment modifies administrative terms of the facility, including reducing the maximum amount per put notice from $2.5 million to $250,000 and increasing the minimum share price threshold for draws to $0.10 per share.